English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

IN BRIEF Artificial pancreas systems are rapidly developing and constitute the most promising technology for insulin-requiring diabetes management. Single-hormone systems (SH-AP) that deliver only insulin and have a hybrid design that necessitates patients’ interventions around meals and exercise are the first to appear on the market. Trials with SH-AP have demonstrated improvement in time spent with blood glucose levels within target ranges, with a concomitant decrease in hypoglycemia. Longer and larger trials involving different patient populations are ongoing to further advance this important technology.

Single-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges